Risk or protective predictors | Sub-group | n (%) | Reference for categoric-al variables | Univariate cox proportional hazard regression (n = 487) | Multivariate cox proportional hazard regression | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Complete case analysis (CCA) (n = 277) | After Multiple imputation (MI) (n = 487) | |||||||||||
Crude HR | 95% C. I | P-value | AHR | 95% C. I | P-value | AHR | 95% C. I | P-value | ||||
Age (Years) | 0.987 | 0.985–0.995 | 0.001** | 0.997 | 0.986–1.008 | 0.59 | 0.988 | 0.980–0.997 | 0.006** | |||
Gender | Male | 220 (45.2%) | 0.909 | 0.751–1.10 | 0.327 | 0.945 | 0.737–1.21 | 0.66 | 0.862 | 0.708–1.05 | 0.14 | |
Female | 267 (54.8%) | 1 | ||||||||||
Bothersome side effects | No | 331 (83.8%) | 0.713 | 0.541–0.938 | 0.016** | 1.09 | 0.79–1.51 | 0.60 | 1.256 | 0.967–1.632 | 0.087 | |
Yes | 64 (16.2%) | 1 | ||||||||||
Substance use | No | 337 (87.5%) | 0.806 | 0.556–1.167 | 0.253 | 0.836 | 0.54–1.29 | 0.42 | 0.781 | 0.560–1.089 | 0.145 | |
Yes | 48 (12.5%) | 1 | ||||||||||
Un- optimization of IAD dose before any change | Un-optimized | 277 (56.3%) | 1.446 | 1.18–1.77 | 0.000** | 1.36 | 1.06–1.76 | 0.02** | 1.35 | 1.046–1.745 | 0.022** | |
Optimized | 147 (34.7%) | 1 | ||||||||||
Comorbid anxiety | Absent | 207 (44.6%) | 1.42 | 1.165–1.732 | 0.001** | 0.69 | 0.54–0.88 | 0.003** | 0.756 | 0.617–0.926 | 0.007** | |
Present | 257 (55.4%) | 1 | ||||||||||
First experience episode | No | 205 (44.6%) | 1.273 | 1.044–1.552 | 0.017** | 1.16 | 0.904–1.48 | 0.24 | 1.188 | 0.966–1.460 | 0.102 | |
Yes | 255 (55.4%) | 1 |